Buradasınız

Anasayfa » Content

Kronik miyeloproliferatif hastalık ve miyelodisplastik sendrom olgularında Jak2 V617F mutasyonu

JAK2 V617F mutation in cases with chronic myeloproliferative disorders and myelodysplastic syndrome

Journal Name:

  • Gülhane Tıp Dergisi

Publication Year:

  • 2009

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
JAK2 gene V617F mutation is reportedly important in chronic myeloproliferative diseases. In this study results of JAK2 V617F mutation in cases with chronic myeloproliferative disease and myelodysplastic syndrome are presented. The study was conducted with 22 patients diagnosed to have chronic myeloproliferative disease and myelodysplastic syndrome (seven polycythemia vera, three essential thrombocythemia, three chronic myelocytic leukemia, five unclassified chronic myeloproliferative disease, three myelodysplastic syndrome and one juvenile myelomonocytic leukemia) and with 10 control cases (seven secondary erytrocytosis and three reactive thrombocythosis). The mutation was detected in six out of seven polycythemia vera cases (85.7%). No mutation was detected in seven cases with secondary erytrocytosis. In one out of the three essential thrombocythemia cases (33.3%), the mutation was detected. No mutation was found in three cases with reactive thrombocythosis and in three cases with chronic myelocytic leukemia. In one out of five cases with unclassified chronic myeloproliferative disease (20%), the JAK2 V617F mutation was positive. No mutation was detected in three cases with myelodysplastic syndrome and juvenile myelomonocytic leukemia. As a result, determination of the JAK2 V617F mutation seems to be important in patients suspected to have chronic myeloproliferative disease, especially in the differential diagnosis of polycythemia vera and secondary polycythemia.
Bookmark/Search this post with
Abstract (Original Language): 
Kronik miyeloproliferatif hastalıklarda JAK2 geni V617F mutasyonunun önemli olduğu bildirilmiştir. Çalışmamızda kronik miyeloproliferatif hastalık ve miyelodisplastik sendromlu olgularda JAK2 V617F mutasyon sonuçları sunulmaktadır. Çalışma kronik miyeloproliferatif hastalık ve miyelodisplastik sendrom tanısı konulan 22 olgu (yedi polisitemia vera, üç esansiyel trombositemi, üç kronik miyelositer lösemi, beş sınıflandırılamayan tip kronik miyeloproliferatif hastalık, üç miyelodisplastik sendrom ve bir juvenil miyelomonositik lösemi) ile 10 kontrol olgusunda (yedi sekonder eritrositoz ve üç reaktif trombositoz) gerçekleştirildi. Yedi polisitemia veralı olgudan altı- sında (%85.7) mutasyon tespit edildi. Yedi sekonder eritrositoz olgusunda mutasyon tanımlanmadı. Üç esansiyel trombositemi olgusundan birisinde (%33.3) mutasyon bulundu. Üç reaktif trombositoz olgusunda ve üç kronik miyelositer lösemi olgusunda mutasyon bulunmadı. Beş sınıflandırılamayan tip kronik miyeloproliferatif hastalık olgusundan birisinde (%20) JAK2 V617F mutasyonu saptandı. Üç miyelodisplastik sendromlu olgu ile juvenil miyelomonositik lösemili olguda mutasyon gösterilmedi. Sonuç olarak, JAK2 V617F mutasyonunun araştırılması kronik miyeloproliferatif hastalık düşünülen olgularda özellikle polistemia vera ile sekonder polisteminin ayı- rıcı tanısında önemli olarak görünmektedir.
FULL TEXT (PDF): 
PDF icon arastirmax-kronik-miyeloproliferatif-hastalik-miyelodisplastik-sendrom-olgularinda-jak2-v617f-mutasyonu.pdf
  • 3
137-140
  • Turkish

REFERENCES

References: 

Kaynaklar
1. Mc Lornan DP, Percy MJ, Jones AV, Cross NC, Mc Mullin
MF. Chronic neutrophilic leukemia with an associated
V617F JAK2 tyrosine kinase mutation. Haematologica
2005; 90: 1696-1697.
2. Baxter EJ, Scott LM, Campbell PJ, et al. Cancer Genome
Project. Acquired mutation of the tyrosine kinase JAK2
in human myeloproliferative disorders. Lancet 2005;
365: 1054-1061.
3. Kaushansky K. The chronic myeloproliferative disorders
and mutation of JAK2: Dameshek’s 54 year old
speculation comes of age. Best Pract Res Clin Haematol
2007; 20: 5-12.
4. Albitar M, Manshouri T, Shen Y, et al. Myelodysplastic
syndrome is not merely “preleukemia”. Blood 2002;
100: 791-798.
5. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang
JC, Schimmer AD. Myelodysplastic syndromes: the
complexity of stem-cell diseases. Nat Rev Cancer 2007;
7: 118-129.
6. Tefferi A, Vardiman JW. Classification and diagnosis of
myeloproliferative neoplasms: The 2008 World Health
Organization criteria and point-of-care diagnostic
algorithms. Leukemia 2008; 22: 14-22.
7. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of
the JAK2 V617F mutation in chronic myeloproliferative
disorders. Blood 2005; 106: 2162-2168.
8. Nevruz O, Guran S, Beyan C ve ark. Kronik miyelositer
lösemi dışı kronik miyeloproliferatif hastalığı olan
olgularımızda sitogenetik inceleme sonuçları. Gülhane
Tıp Dergisi 2005; 47: 11-13.
9. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12
mutations in polycythemia vera and idiopathic
erythrocytosis. N Engl J Med 2007; 356: 459-468.
10. Wang YL, Vandris K, Jones A, et al. JAK2 mutations
are present in all cases of polycythemia vera. Leukemia
2008; 22: 1289.
11. Tefferi A, Spivak JL. Polycythemia vera: scientific
advances and current practice. Semin Hematol 2005;
42: 206-220.
12. Tefferi A, Sirhan S, Lasho TL, et al. Concomitant
neutrophil JAK2 mutation screening and PRV-1
expression analysis in myeloproliferative disorders and
secondary polycythaemia. Br J Haematol 2005; 131:
166-171.140 • Eylül 2009 • Gülhane Tıp Derg Kozan ve ark.
13. Scott LM, Beer PA, Bench AJ, Erber WN, Green AR.
Prevalance of JAK2 V617F and exon 12 mutations in
polycythaemia vera. Br J Haematol 2007; 139: 511-512.
14. Butcher CM, Hahn U, To LB, et al. Two novel JAK2 exon
12 mutations in JAK2V617F-negative polycythaemia
vera patients. Leukemia 2008; 22: 870-873.
15. Schafer AI. Molecular basis of the diagnosis and
treatment of polycythemia vera and essential
thrombocythemia. Blood 2006; 107: 4214-4222.
16. Campbell PJ, Scott LM, Buck G, et al. United Kingdom
Myeloproliferative Disorders Study Group; Medical
Research Council Adult Leukaemia Working Party;
Australasian Leukaemia and Lymphoma Group.
Definition of subtypes of essential thrombocythaemia
and relation to polycythaemia vera based on JAK2
V617F mutation status: a prospective study. Lancet
2005; 366: 1945-1953.
17. Gangat N, Wolanskyj AP, McClure RF, et al. Risk
stratification for survival and leukemic transformation
in essential thrombocythemia: a single institutional
study of 605 patients. Leukemia 2007; 21: 270-276.
18. Levine RL, Belisle C, Wadleigh M, et al. X-inactivationbased clonality analysis and quantitative JAK2V617F
assessment reveal a strong association between clonality
and JAK2V617F in PV but not ET/MMM, and identifies
a subset of JAK2V617F-negative ET and MMM patients
with clonal hematopoiesis. Blood 2006; 107: 4139-4141.
19. Gale RE, Allen AJ, Nash MJ, Linch DC. Long-term serial
analysis of X-chromosome inactivation patterns and
JAK2 V617F mutant levels in patients with essential
thrombocythemia show that minor mutant-positive
clones can remain stable for many years. Blood 2007;
109: 1241-1243.
20. Neuwirtova R, Mocikova K, Musilova J, et al. Mixed
myelodysplastic and myeloproliferative syndromes.
Leuk Res 1996; 20: 717-726.
21. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2
V617F activating tyrosine kinase mutation is an
infrequent event in both “atypical” myeloproliferative
disorders and myelodysplastic syndromes. Blood 2005;
106: 1207-1209.
22. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation
1849G>T is rare in acute leukemias but can be found
in CMML, Philadelphia chromosome-negative CML,
and megakaryocytic leukemia. Blood 2005; 106:
3370-3373.
23. Koike K, Matsuda K. Recent advances in the pathogenesis
and management of juvenile myelomonocytic
leukaemia. Br J Haematol 2008; 141: 567-575.
24. Bayraktar Y, Harmanci O, Büyükasik Y, et al. JAK2V617F
mutation in patients with portal vein thrombosis. Dig
Dis Sci 2008; 53: 2778-2783.

Thank you for copying data from http://www.arastirmax.com